Publications associées à Metal-based drugs that break the rules

Impact of the plasma operation on the technical requirements in EU-DEMO

Olivier Sauter, Minh Quang Tran, Hartmut Zohm, Emiliano Fable, Simon Van Mulders

The plasma design point during stationary phase operation of EU-DEMO has been described extensively in the past, and the assumptions employed for its definition have been supported by various investigations. However, a stationary snapshot is by far not suf ...

2022

Classification of Metal-Based Drugs according to Their Mechanisms of Action

Paul Joseph Dyson

Metal-based drugs and imaging agents are extensively used in the clinic for the treatment and diagnosis of cancers and a wide range of other diseases. The current clinical arsenal of compounds operate via a limited number of mechanisms, whereas new putativ ...

CELL PRESS2020

Computational characterisation of the selectivity and binding mode of mono- and binuclear transition metal based anticancer compounds

Thibaud Edouard Alistair von Erlach

The rising resistance and the severe side effects associated with classical anticancer drugs such as cisplatin or mercaptopurines has triggered the development of novel antitumourous agents based on transition metal (e.g. ruthenium, osmium, and gold) organ ...

EPFL2020

Recent Considerations in the Application of RAPTA-C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Magdalena Rausch

The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA - 1,3,5-triaza-7-phosphaadamantane compound, RAPTA-C, represents an innovative anti-cancer therapeutic and a better-tolerated alternative to platinum (Pt)-based chemotherapeutic drugs in the treatment ...

WILEY2019

Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis

Gerardo Turcatti, Damiano Banfi, Paul Joseph Dyson, Fabien Kuttler, Hristo Plamenov Varbanov

Drug combinations are extensively used to treat cancer and are often selected according to complementary mechanisms. Here, we describe a cell-based high-throughput screening assay for identification of synergistic combinations between broadly applied plati ...

2019

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

Paul Joseph Dyson, Gianni Sava

Platinum drugs are extensively used in the clinic to treat cancer, often leading to a palliative response rather than a cure. While DNA is considered to be the primary target of platinum drugs, there is no clear relationship between cellular platinum accum ...

2018

Application of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research

Paul Joseph Dyson, Anders Meibom, Sarah Theiner

Mass spectrometry imaging is being increasingly used in metal-based anticancer drug development to study elemental and/or molecular drug distributions in different biological systems. The main analytical tools employed are SIMS (especially nanoSIMS), LA-IC ...

Royal Society of Chemistry2017

Controlling and Monitoring Intracellular Drug Delivery Using PHPMA-Based Polymer Nanomedicines

Claudia Battistella

Polymer nanomedicine is an attractive approach for the delivery of anticancer drugs. Firstly designed to increase drug bioavailability, polymer conjugates and polymer nanoparticles have rapidly emerged in the field of cancer therapy after the discovery of ...

EPFL2017

Development of mass spectrometric methods to understand the mechanism of action of transition metal-based anticancer compounds

Fook Seng Ronald Lee

Metal based anti-cancer drugs (metallodrugs) such as cisplatin are a cornerstone of cancer chemotherapy. However, development of this class of compound has been hindered by our lack of understanding of how they function. This is mainly because existing met ...

EPFL2016

Multidimensional Texture Analysis for Improved Prediction of Ultrasound Liver Tumor Response to Chemotherapy Treatment

Adrien Raphaël Depeursinge, Dimitri Nestor Alice Van De Ville

The number density of scatterers in tumor tissue contribute to a heterogeneous ultrasound speckle pattern that can be difficult to discern by visual observation. Such tumor stochastic behavior becomes even more challenging if the tumor texture heterogeneit ...

Springer2016

In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(eta(6)-p-cymene)-Cl-2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas

Paul Joseph Dyson, Maxime Dubois, Patrycja Nowak-Sliwinska

Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin, carboplatin and oxaliplatin, a variety of other metal-based anti-cancer compounds are being investigated. In particular, a number of ruthenium-based compounds have been id ...

2014

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

Paul Joseph Dyson, Ursula Röthlisberger, Wee Han Ang, Pablo Campomanes Ramos, Alexey Nazarov, Michael Groessl, Catherine Marie Amélie Clavel

Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly ...

Nature Research2014

Rational design of organic and organometallic thermoresponsive or tumor-selective anticancer drugs and their in vitro and in vivo biological evaluation

Catherine Marie Amélie Clavel

Conventional chemotherapy leads to severe side-effects such as nephrotoxicity, nausea and vomiting and fatigue along with drug resistance. Alkylating agents used to treat cancer were even shown to provoke second cancers, often years after the end of chemot ...

EPFL2014

Cluster-Surface Interaction and Catalytic Activity : Platinum on TiO2

Simon Bonanni

This thesis is devoted to the study of the catalytic activity of small supported metal clusters. The TiO2(110)-(1×1) supported platinum cluster activity towards CO oxidation, its correlation with the cluster morphology, support properties, and the cluster ...

EPFL2012

Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation

Paul Joseph Dyson, Ursula Röthlisberger, Wee Han Ang, Pablo Campomanes Ramos

Platinum-based cancer drugs, such as cisplatin, are highly effective chemotherapeutic agents used extensively for the treatment of solid tumors. However, their effectiveness is limited by drug resistance, which, in some cancers, has been associated with an ...

Wiley-Blackwell2011

Metal-based antitumour drugs in the post-genomic era: what comes next?

Paul Joseph Dyson, Gianni Sava

In our Dalton Transactions Perspective article entitled, 'Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929-1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era wo ...

2011

DNA Reactivity Profile of trans-Platinum Planar Amine Derivatives

Alexey Nazarov

New trans-platinum planar amines (TPAs) represent a family of platinum-based drugs with cytotoxicity equivalent to that of cisplatin, but with negligible cross-resistance. According to the substitution pattern around the metal center, distinct DNA adducts ...

2011

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation

Paul Joseph Dyson, Alexey Nazarov

Heavy metal compounds have toxic and medicinal potential through capacity to form strong specific bonds with macromolecules, and the interaction of platinum drugs at the major groove nitrogen atom of guanine bases primarily underlies their therapeutic acti ...

Oxford University Press2011

Characterization of New Potential Anticancer Drugs Designed To Overcome Glutathione Transferase Mediated Resistance

Paul Joseph Dyson, Wee Han Ang, Jie Zhang

Resistance against anticancer drugs remains a serious obstacle in cancer treatment. Here we used novel strategies to target microsomal glutathione transferase 1 (MGST1) and glutathione transferase pi (GSTP) that are often overexpressed in tumors and confer ...

2011

Next-Generation Anticancer Metallodrugs

Angela Casini

More than 99% of currently approved clinical drugs are organic compounds. In contrast, the percentage of metal-containing drugs (metallodrugs) is very low. In cancer chemotherapy, however, platinum coordination compounds represented by cisplatin and deriva ...

2010